Research peptides in Canada: Health Canada's position and import considerations

The question Canadian labs ask

Canadian laboratories that order peptides from foreign catalogs want two answers: is the product lawful to buy, and will the shipment clear the border. Canadian law does not answer either question by product name. It asks how a substance is manufactured, sold or represented, and who is importing it for what purpose. [4] [6]

This guide sets out what Health Canada and the Canada Border Services Agency (CBSA) had published as of 30 October 2026, using their own pages. It is a documentation guide for laboratory procurement. It does not give legal advice, does not cover any use in people or animals, and does not say whether a particular order will be admitted. Where the official pages are silent, we say so rather than fill the gap.

How the Food and Drugs Act defines a drug

Section 2 of the Food and Drugs Act says a drug includes any substance or mixture of substances "manufactured, sold or represented for use in" the diagnosis, treatment, mitigation or prevention of disease in humans or animals, in restoring, correcting or modifying organic functions, or in disinfecting premises where food is made or kept. [4]

Two other definitions in the same section matter to a buyer. "Sell" includes offering, exposing or holding for sale and distributing to one or more persons whether or not anything is paid. "Advertisement" includes any representation by any means for the purpose of promoting the sale of a drug, directly or indirectly. [4] The practical point is that the seller's whole presentation counts, not only the label on the vial.

Under section C.01.014 of the Food and Drug Regulations, no manufacturer may sell a drug in dosage form unless a Drug Identification Number (DIN) has been assigned and not cancelled. The section exempts some categories, including veterinary health products and study drugs as defined elsewhere in the Regulations. [5] Health Canada's advisories tell readers that an authorized product carries an eight-digit DIN, with the 2025 advisories also naming a Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM) for natural and homeopathic products. [1] [2] [3]

What Health Canada has said about peptides

On 9 April 2026 Health Canada issued a public advisory about injectable peptides bought online. It says peptides are "generally regulated as prescription drugs" in Canada, that it keeps finding products marketed as "For Research Use Only, Not for Human Consumption", and that "this type of labelling does not make these products legal or exempt from regulatory requirements." It also says it is working with CBSA to stop unauthorized shipments from entering the country. [1]

The 2026 advisory lists examples of seized unauthorized injectable peptides, including BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, Ipamorelin, KPV, Melanotan I and II, MOTS-C, NAD+, SS-31, TB-500 and retatrutide, and says many other unauthorized peptides exist. [1] Earlier advisories named specific sellers. The table summarises three of them as published.

• None of the three advisories describes a separate pathway for laboratory or in vitro research purchases. Their audience is consumers. [1] [2] [3]
• The 2026 advisory tells readers to check authorization by searching Health Canada's Drug Product Database for the product's eight-digit DIN. [1]

What happens at the border

CBSA Memorandum D19-9-1, dated July 2023, explains how CBSA administers Health Canada legislation at the border. CBSA may detain goods under the Customs Act and refer them to Health Canada, which gives the admissibility recommendation and may follow up with the importer. Beyond the initial detention, CBSA's own enforcement is limited to Customs Act contraventions. [6]

The memorandum treats a shipment as commercial when, for example, it goes to a retailer, distributor or other commercial establishment, or exceeds a 90-day supply. Drugs imported for sale must carry a DIN, and commercial importers of human and veterinary drugs must hold a Drug Establishment Licence that lists the foreign manufacturing site. It also notes that under section C.01.045 importation of prescription drugs is restricted to practitioners, manufacturers, wholesale druggists, registered pharmacists and visiting non-residents, and that Canadian residents may not import prescription drugs by mail or courier. [6]

D19-9-1 does not address laboratory or research use of drugs directly. It mentions clinical trial shipments and research authorizations for pest control products, and directs other questions to Health Canada. It also says importers may be held responsible for all costs tied to inadmissible goods. [6]

What a Canadian lab should keep on file

Because the official pages turn on presentation, purpose and importer status, the useful file answers those three points. The checklist below is a record list, not a compliance opinion. If your institution has a controlled goods or research compliance office, its instructions take precedence.

• Supplier legal entity, country and website as captured on the order date, including the product page and terms of sale.
• A purchase order that states the laboratory purpose in plain terms, without any reference to use in people or animals.
• The importer of record and the basis your institution relies on for importing, with any written guidance obtained from Health Canada.
• The lot certificate of analysis and safety data sheet. D19-9-1 notes that CBSA has discretion over hazardous products when a safety data sheet is missing. [6]
• Customs paperwork, any CBSA detention notice and any Health Canada correspondence, kept with the receiving record.
• A dated note checking whether the supplier or product name appears in a Health Canada advisory. [1] [2] [3]

Limits of this guide

This guide does not say whether a given peptide is a drug, whether a specific shipment will be admitted, or whether any supplier is lawful. It does not cover controlled substances, which CBSA handles under a separate memorandum, D19-9-2. [7] It relies on pages read on 30 October 2026; advisories and memoranda change, so re-check the dates on each source before you rely on them.